上海弘升科技發展有限公司

上海弘升科技發展有限公司
上海弘升科技發展有限公司

当前位置:弘升科技 > 公司简介

测量应用案例-20210403

2021-05-17 18:46:09

422

文献名:Eradicating intracellular MRSA via targeted delivery of lysostaphin and vancomycin with mannose-modified exosomes

 

 

上海弘升科技發展有限公司Xiaohong Yangab; Beibei Xieb; Haibo Pengb; Gongming Shib; Banne Sreenivasb; Jian Guob; Chenhui Wangb; Yun Heb

a  Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, 266 Fangzheng Ave, Shuitu Technology Development Zone, Beibei, 400714 Chongqing, China

b  Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, School of Pharmaceutical Sciences, Chongqing University, 55 Daxuecheng South Road, Shapingba, 401331 Chongqing, China

 

 

 

摘要:Intracellular methicillin-resistant Staphylococcus aureus (MRSA) is extremely difficult to remove by common antibiotics, leading to infection recurrence and resistance. Herein we report a novel exosome-based antibiotic delivery platform for eradicating intracellular MRSA, where mannosylated exosome (MExos) is employed as the drug carrier and preferentially taken up by macrophages, delivering lysostaphin (MExoL) and vancomycin (MExoV) to intracellular pathogens. Combination of MExoL and MExoV eradicated intracellular quiescent MRSA. Moreover, MExos rapidly accumulated in mouse liver and spleen, the target organs of intracellular MRSA, after intravenous (IV) administration. Thus, the MExos antibiotic delivery platform is a promising strategy for combating intracellular infection.

 

 

关键词:Exosomes; Surface functionalization; Antibiotics; Targeted delivery; Intracellular infection


分享到微信朋友圈

分享到其他

010-51627740

上海弘升科技發展有限公司 上海弘升科技發展有限公司
上海弘升科技發展有限公司